ABUS

Arbutus Biopharma Corp (ABUS) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically developing imdusiran (AB-729) and AB-101 for chronic hepatitis B (cHBV). The company is also actively litigating patent infringement claims against Moderna and Pfizer/BioNTech regarding its lipid nanoparticle (LNP) delivery technology. In Q2 2025, the company terminated its strategic partnership with Qilu Pharmaceutical, regaining global rights to imdusiran.

Key Financial Metrics

Note: Q2 2025 Net Income was driven by a one-time revenue recognition event. The company reported a net loss for the six-month period.

Material Changes vs. Prior Period

• Revenue Surge: Q2 2025 revenue increased 522% year-over-year, primarily due to the recognition of $9.6 million in previously deferred revenue following the termination of the Qilu Pharmaceutical partnership in June 2025.
• Restructuring Costs: The company incurred $12.5 million in restructuring costs during the first six months of 2025 (including $12.4 million in Q1). This followed a 57% workforce reduction, the exit of the Warminster, PA headquarters, and the discontinuation of in-house scientific research.
• Expense Reduction: Excluding restructuring, operating expenses decreased significantly. R&D expenses dropped $10.1 million in Q2 and $16.5 million for the six months compared to 2024, reflecting the cessation of discovery efforts and the IM-PROVE III trial.
• Liquidity Position: Total cash and investments decreased to $98.1 million from $122.6 million at year-end 2024, driven by operating cash burn and net investment outflows, though the company maintains a runway of at least 12 months.

Outlook, Risks, and Management Commentary

• Strategic Pivot: Management has streamlined operations to focus exclusively on advancing imdusiran and AB-101. The company expects significantly reduced net cash burn in 2025 compared to 2024.
• Patent Litigation:
  • Moderna: Summary judgment phase began in July 2025; trial set for March 2026. Five international lawsuits filed in March 2025 targeting 30 countries.
  • Pfizer/BioNTech: Fact discovery is ongoing; claim construction ruling timing is uncertain but could occur in 2025.
• Clinical Progress:
  • IM-PROVE I: Data showed a 50% functional cure rate in HBeAg-negative patients with baseline HBsAg <1000 IU/mL using imdusiran + IFN.
  • IM-PROVE II: Data showed a 25% functional cure rate in a cohort receiving imdusiran + VTP-300 + low-dose nivolumab.
  • AB-101: Phase 1a/1b trial ongoing; Part 3 data presented in May 2025 showed good tolerability and high receptor occupancy.
  • Risks: Continued reliance on litigation outcomes for potential monetization; need for additional capital to fund clinical trials; uncertainty regarding the reversion of royalty rights from OMERS.

  Investor Verification Checklist

  • Revenue Quality: Verify the sustainability of revenue streams post-Qilu termination, as the $9.6M recognized in Q2 was a one-time event.
  • Cash Burn Rate: Monitor the actual reduction in operating expenses against management's guidance for reduced cash burn in 2025.
  • Litigation Timeline: Track the summary judgment phase in the Moderna US case and the claim construction ruling in the Pfizer/BioNTech case, as these are critical for potential upside.
  • Clinical Data: Review upcoming data readouts for the IM-PROVE trials to confirm functional cure rates in broader patient populations.
  • Capital Needs: Assess the timeline for potential future equity raises given the $98M liquidity position and ongoing development costs.